Citations

Showing 10 of 108094 citations.

Vergleich von transbronchialer Zangen- und Kryobiopsie bei Patienten mit histologischem Nachweis Sarkoidose-typischer Granulome
Häntschel, M, Eberhardt, Ralf , Petermann, Christoph, Gesierich, W, Darwiche, Kaid , Hagmeyer, L, Colby, Thomas V. , Fend, F, Theegarten, Dirk , Wintzer, H O, Kreuter, Michael , Spengler, W., Behrens-Zemek, A F, Lewis, Richard A. , Böckeler, M, Hetzel, Juergen , Hagmeyer, L, Wintzer, Hanns-Olof, Spengler, W, Lewis, R A, Evrard, HC , Ehab, Ahmed , Böckeler, Michael

Mayo Clinic

Pneumologie | June 8, 2022 | Volume: 76 | Issue: S 01 | Pages: S82-S82

10.1055/s-0042-1747879 Get It

Effects of nintedanib in patients with progressive fibrosing interstitial lung disease associated with rheumatoid arthritis (RA-ILD) in the INBUILD trial*
Koschel, D, Matteson, E. L., Mueller, Heiko , Moros, L, Rohr, K B, Koschel, D, Kelly, Clive Anthony , Aringer, Martin , Burmester, Gerd R , Moros, Lizette, Rohr, K B, Kolb, Martin R.J.

Mayo Clinic

Pneumologie | June 8, 2022 | Volume: 76 | Issue: S 01 | Pages: S21-S21

10.1055/s-0042-1747733 Get It

Rates of Response to Atogepant for Migraine Prophylaxis Among Adults
Blumenfeld, Andrew , McAllister, Peter , Lu, Kaifeng , Dabruzzo, Brett , Miceli, Rosa, Severt, Lawrence, Finnegan, Michelle , Trugman, Joel M. , Lipton, Richard B. , Pozo‐Rosich, Patricia , Dodick, David W. , Li, Ye

Mayo Clinic

JAMA Network Open | June 8, 2022 | Volume: 5 | Issue: 6 | Pages: e2215499

10.1001/jamanetworkopen.2022.15499 | PMID 35675076 Get It

Clinical efficacy of mychophenolate mofetil in treating lichen planopilaris
Azizpour, Arghavan , Hatami, Parvaneh , Lajevardi, Vahideh, Mohammadi, Mehran, Aghazadeh, Nessa , Hatami, Parvaneh , Aghazadeh Mohandesi, Nessa , Lajevardi, Vahide , Aryanian, Zeinab

Mayo Clinic

Dermatologic Therapy | June 8, 2022 | Volume: 35 | Issue: 8 | Pages: No page available

10.1111/dth.15625 | PMID 35674693 Get It

Nomenclature and diagnosis of seronegative coeliac disease and chronic non-coeliac enteropathies in adults: the Paris consensus
Schiepatti, Annalisa , Sanders, David S. , Baiardi, Paola , Caio, Giacomo , Ciacci, Carolina , Kaukinen, Katri , Lebwohl, Benjamin , Leffler, Daniel A. , Murray, Joseph A. , Rostami, Kamran , Volta, Umberto , Biagi, Federico , Malamut, Georgia , Murray, J A , Ciacci, Carolina , Malamut, Georgia , Rubio‐Tapia, Alberto

Mayo Clinic

Gut | June 8, 2022 | Volume: 71 | Issue: 11 | Pages: 2218-2225

10.1136/gutjnl-2021-326645 | PMID 35676085 Get It

Objective Differential diagnosis of villous atrophy (VA) without coeliac antibodies in adults includes seronegative coeliac disease (CD) and chronic enteropathies unrelated to gluten, ie. non-coeliac enteropathies (NCEs). There is currently no international consensus on the nomenclature and diagnostic criteria for these enteropathies. In this work, a Delphi process was conducted to address this diagnostic and clinical uncertainty. Design An international task force of 13 gastroenterologists from six countries was recruited at the 16th International Coeliac Disease Symposium, Paris, 2019. Between September 2019 and July 2021, a Delphi process was conducted through mail surveys to reach a consensus on which conditions to consider in the differential diagnosis of VA with negative coeliac serology and the clinical diagnostic approaches required for these conditions. A 70% agreement threshold was adopted. Results Chronic enteropathies characterised by VA and negative coeliac serology can be attributed to two main clinical scenarios: forms of CD presenting with negative serology, which also include seronegative CD and CD associated with IgA deficiency, and NCEs, with the latter recognising different underlying aetiologies. A consensus was reached on the diagnostic criteria for NCEs assisting clinicians in differentiating NCEs from seronegative CD. Although in adults seronegative CD is the most common aetiology in patients with VA and negative serology, discriminating between seronegative CD and NCEs is key to avoid unnecessary lifelong gluten-free diet, treat disease-specific morbidity and contrast poor long-term outcomes. Conclusion This paper describes the Paris consensus on the definitions and diagnostic criteria for seronegative CD and chronic NCEs in adults.
Durability analysis of the highly effective BNT162b2 vaccine against COVID-19
Puranik, Arjun, Lenehan, Patrick J. , O’Horo, John C. , Pawlowski, Colin , Niesen, Michiel J.M. , Virk, Abinash , Swift, Melanie D. , Kremers, Walter K. , Gordon, Joel , Geyer, Holly L. , Speicher, Leigh L. , Gordon, Joel E, Speicher, Leigh Lewis, Soundararajan, Venky , O'Horo, John C , Swift, Melanie D , Lenehan, Patrick J , Kremers, Walter K , Venkatakrishnan, A J , Soundararajan, Venky , Badley, Andrew D.

Mayo Clinic

PNAS Nexus | June 8, 2022 | Volume: 1 | Issue: 3 | Pages: No page available

10.1093/pnasnexus/pgac082 | PMID 35832867 Get It

Abstract COVID-19 vaccines are effective, but breakthrough infections have been increasingly reported. We conducted a test-negative case-control study to assess the durability of protection after full vaccination with BNT162b2 against polymerase chain reaction (PCR)-confirmed symptomatic SARS-CoV-2 infection, in a national medical practice from January 2021 through January 2022. We fit conditional logistic regression (CLR) models stratified on residential county and calendar time of testing to assess the association between time elapsed since vaccination and the odds of symptomatic infection or non-COVID-19 hospitalization (negative control), adjusted for several covariates. There were 5,985 symptomatic individuals with a positive test after full vaccination with BNT162b2 (cases) and 32,728 negative tests contributed by 27,753 symptomatic individuals after full vaccination (controls). The adjusted odds of symptomatic infection were higher 250 days after full vaccination versus at the date of full vaccination (Odds Ratio [OR]: 3.62, 95% CI: 2.52 to 5.20). The odds of infection were still lower 285 days after the first BNT162b2 dose as compared to 4 days after the first dose (OR: 0.50, 95% CI: 0.37 to 0.67), when immune protection approximates the unvaccinated status. Low rates of COVID-19 associated hospitalization or death in this cohort precluded analyses of these severe outcomes. The odds of non-COVID-19 associated hospitalization (negative control) decreased with time since vaccination, suggesting a possible underestimation of waning protection by this approach due to confounding factors. In summary, BNT162b2 strongly protected against symptomatic SARS-CoV-2 infection for at least 8 months after full vaccination, but the degree of protection waned significantly over this period.
Beyond the AJR: Validation and Algorithmic Audit of a Deep Learning System to Detect Hip Fractures Radiographically
Stanborough, Rupert O. , Garner, Hillary W.

Mayo Clinic

American Journal of Roentgenology | June 8, 2022 | Volume: 220 | Issue: 1 | Pages: 150-150

10.2214/ajr.22.28053 | PMID 35674349 Get It

Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study
Nowakowski, Grzegorz S. , Yoon, Dok Hyun , Peters, Anthea , Mondello, Patrizia , Joffe, Erel , Fleury, Isabelle , Greil, Richard , Ku, Matthew , Marks, Reinhard , Kim, Kibum , Huang, Dan , Waltl, Eva E., Winderlich, Mark, Kurukulasuriya, Nuwan, Ambarkhane, Sumeet, Salles, Gilles A , Mondello, Patrizia , Ku, Matthew , Zinzani, Pier Luigi , Trotman, Judith , Heß, Georg , Salles, Gilles

Mayo Clinic

Clinical Cancer Research | June 8, 2022 | Volume: 28 | Issue: 18 | Pages: 4003-4017

10.1158/1078-0432.ccr-21-3648 | PMID 35674661 Get It

Purpose: In RE-MIND2 (NCT04697160), patient-level outcomes from the L-MIND study (NCT02399085) of tafasitamab plus lenalidomide were retrospectively compared with patient-level matched observational cohorts treated with National Cancer Care Network (NCCN)/European Society for Medical Oncology (ESMO)-listed systemic therapies for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Patients and Methods: Data were collected from health records of eligible patients aged ≥18 years with histologically confirmed DLBCL who had received ≥2 systemic therapies for DLBCL (including ≥1 anti-CD20 therapy). Patients from L-MIND were matched with patients from the RE-MIND2 observational cohort using estimated propensity score-based 1:1 nearest-neighbor matching, balanced for nine covariates. The primary analysis compared tafasitamab plus lenalidomide with patients who received any systemic therapy for R/R DLBCL (pooled in one cohort) or bendamustine plus rituximab (BR) or rituximab plus gemcitabine and oxaliplatin (R-GemOx; as two distinct cohorts). The primary endpoint was overall survival (OS). Secondary endpoints included treatment response and time-to-event outcomes. Results: In RE-MIND2, 3,454 patients were enrolled from 200 sites in North America, Europe, and Asia-Pacific. Strictly matched pairs of patients consisted of tafasitamab plus lenalidomide versus systemic therapies pooled (n = 76 pairs), versus BR (n = 75 pairs), and versus R­GemOx (n = 74 pairs). Significantly prolonged OS was reported with tafasitamab plus lenalidomide versus systemic pooled therapies [hazard ratios (HR): 0.55; P = 0.0068], BR (HR: 0.42; P < 0.0001), and R-GemOx (HR: 0.47; P = 0.0003). Conclusions: RE-MIND2, a retrospective observational study, met its primary endpoint, demonstrating prolonged OS with tafasitamab plus lenalidomide versus BR and R-GemOx. See related commentary by Cherng and Westin, p. 3908
Multi‐ancestry genome‐wide association study of asthma exacerbations
Herrera‐Luis, Esther , Ortega, Victor E. , Ampleford, Elizabeth J., Granell, Raquel , Roos, Emmely W. de , Terzikhan, Natalie, Vergara, Ernesto Elorduy , Hernandez‐Pacheco, Natalia , Pérez-García, Javier , Martín-González, Elena , Lorenzo-Díaz, Fabián , Group, U‐BIOPRED Study, Jorgensen, Andrea , Forno, Erick , Lethem, Ryan, Espuela‐Ortiz, Antonio , Eng, Celeste , Pérez, José María Hernández , Hawkins, Greg, Marsico, Annalisa , Bahmer, Thomas , Hansen, Gesine , Kopp, Matthias , Rios, Raimon, Cruz, María Jesús , González‐Barcala, Francisco Javier , Olaguibel, José María , Canino, Glorisa , Cloutier, Michelle M. , Rodríguez‐Santana, José, Korta‐Murua, Javier , Potočnik, Uroš , Kabesch, Michael , Mukhopadhyay, Somnath , Pirmohamed, Munir , Hawcutt, Daniel B. , Palmer, Colin N.A. , Mutius, Erika von , Celedón, Juan C. , Chew, Fook Tim , Bleecker, Eugene R. , Meyers, Deborah A. , Granell, Raquel , Hernandez-Pacheco, Natalia , Perez-Garcia, Javier , Lorenzo-Diaz, Fabian , Hashimoto, Simone , Yan, Qi , Forno, Erick , Vijverberg, Susanne J , Espuela-Ortiz, Antonio , Gorenjak, Mario , Hernández-Pérez, José M , Poza-Guedes, Paloma , Corcuera, Paula , Olaguibel, José María , Plaza, Vicente , Quirce, Santiago , Cloutier, Michelle , Del Pozo, Victoria , Figueiredo, Camila , Pirmohamed, Munir , Hawcutt, Daniel B , Melén, Erik , Palmer, Colin N A , Turner, Steve , Maitland-van der Zee, Anke H , von Mutius, Erika , Celedón, Juan C , Brusselle, Guy , Chew, Fook Tim , Burchard, Esteban G. , Pino-Yanes, Maria , Sio, Yang Yie , Brinkman, Paul , Group, U‐BIOPRED Study, González‐Pérez, Ruperto , Sardón‐Prado, Olaia , Rabe, Klaus Friedrich , Villar, Jesús

Mayo Clinic

Pediatric Allergy and Immunology | June 8, 2022 | Volume: 33 | Issue: 6 | Pages: No page available

10.1111/pai.13802 | PMID 35754128 Get It

Abstract Background Asthma exacerbations are a serious public health concern due to high healthcare resource utilization, work/school productivity loss, impact on quality of life, and risk of mortality. The genetic basis of asthma exacerbations has been studied in several populations, but no prior study has performed a multi‐ancestry meta‐analysis of genome‐wide association studies (meta‐GWAS) for this trait. We aimed to identify common genetic loci associated with asthma exacerbations across diverse populations and to assess their functional role in regulating DNA methylation and gene expression. Methods A meta‐GWAS of asthma exacerbations in 4989 Europeans, 2181 Hispanics/Latinos, 1250 Singaporean Chinese, and 972 African Americans analyzed 9.6 million genetic variants. Suggestively associated variants ( p ≤ 5 × 10 −5 ) were assessed for replication in 36,477 European and 1078 non‐European asthma patients. Functional effects on DNA methylation were assessed in 595 Hispanic/Latino and African American asthma patients and in publicly available databases. The effect on gene expression was evaluated in silico. Results One hundred and twenty‐six independent variants were suggestively associated with asthma exacerbations in the discovery phase. Two variants independently replicated: rs12091010 located at vascular cell adhesion molecule‐1/exostosin like glycosyltransferase‐2 ( VCAM1 / EXTL2 ) (discovery: odds ratio (OR T allele ) = 0.82, p = 9.05 × 10 −6 and replication: OR T allele = 0.89, p = 5.35 × 10 −3 ) and rs943126 from pantothenate kinase 1 ( PANK1 ) (discovery: OR C allele = 0.85, p = 3.10 × 10 −5 and replication: OR C allele = 0.89, p = 1.30 × 10 −2 ). Both variants regulate gene expression of genes where they locate and DNA methylation levels of nearby genes in whole blood. Conclusions This multi‐ancestry study revealed novel suggestive regulatory loci for asthma exacerbations located in genomic regions participating in inflammation and host defense.